

Approved



Cameroon
Country Operational Plan
FY 2016



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		301,250		301,250	0	301,250
USAID		7,550,639	1,500,000	9,050,639	4,000,000	13,050,639
DOD		553,585		553,585	874,652	1,428,237
PC		955,511		955,511	0	955,511
HHS/CDC	575,119	23,241,187		23,816,306	1,513,057	25,329,363
HHS/HRSA		145,000		145,000	0	145,000
Total	575,119	32,747,172	1,500,000	34,822,291	6,387,709	41,210,000

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency						On Hold Amount	Total
	State	DOD	HHS/CDC	HHS/HRSA	PC	USAID		
HBHC	1,227	4,696	29,739		119,669	1,958,500	0	2,113,831
HKID					60,206	1,404,609	0	1,464,815
HLAB	1,227		275,544				0	276,771
HMBL			48,489				0	48,489
HTXD						69,354	0	69,354
HTXS	1,227	429,511	10,796,893	145,000		1,995,320	0	13,367,951
HVCT	1,227	19,197	1,971,602		1,989	527,269	0	2,521,284
HVMS	263,154	0	1,827,299		549,886	665,575	0	3,305,914
HVOP		9,829			208,846	1,972,115	0	2,190,790
HVSI	27,053		285,681		14,915	64,766	0	392,415
HVTB	1,227		444,509				0	445,736
MTCT	1,227	21,469	2,166,773				0	2,189,469

Approved



OHSS	1,227		208,824			273,991	0	484,042
PDCS	1,227	15,687	1,589,198			5,141	0	1,611,253
PDTX	1,227	53,196	4,171,755			113,999	0	4,340,177
	301,250	553,585	23,816,306	145,000	955,511	9,050,639	0	34,822,291



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	2,006,810	0
HKID	1,447,404	0
HVTB	362,728	0
PDCS	1,582,581	0
Total Technical Area Planned Funding:	5,399,523	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	104,547	0
HVSI	77,250	0
OHSS	180,000	0
Total Technical Area Planned Funding:	361,797	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HMBL	18,750	0
HVCT	2,429,761	0
HVOP	2,048,356	0
MTCT	2,091,592	0
Total Technical Area Planned Funding:	6,588,459	0

Technical Area: Treatment

Approved



Budget Code	Budget Code Planned Amount	On Hold Amount
HTXS	13,137,740	0
PDTX	4,227,558	0
Total Technical Area Planned Funding:	17,365,298	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	95,797
	Number of new ANC and L&D clients	100,152
	By: Known positives at entry	2,174
	By: Number of new positives identified	3,701
	Sum of Positives Status disaggregates	5,875
	Required only for DREAMS Countries - By Number of new positives: <15	
	Required only for DREAMS Countries - By Number of new positives: 15-19	
	Required only for DREAMS Countries - By Number of new positives: 20-24	
	Required only for DREAMS Countries - By Number of known positives: <15	
	Required only for DREAMS Countries - By Number of known	



	positives: 15-19	
	Required only for DREAMS Countries - By Number of known positives: 20-24	
	Required only for DREAMS Countries - Denominator: <15	
	Required only for DREAMS Countries - Denominator: <15-19	
	Required only for DREAMS Countries - Denominator: 20-24	
	Required only for DREAMS Countries - Denominator: 25-49	
	Required only for DREAMS Countries - Denominator: 50+	
	Required only for DREAMS Countries - By Number of known positives: 25-49	
	Required only for DREAMS Countries - By Number of known positives: 50+	
	Required only for DREAMS Countries - By Number of new positives: 25-49	
	Required only for DREAMS Countries - By Number of new positives: 50+	
	By Age (DREAMS SNU's ONLY): <15	
	By Age (DREAMS SNU's ONLY): 15-19	
	By Age (DREAMS SNU's ONLY): 20-24	
	By Age (DREAMS SNU's ONLY): 25-49	



	By Age (DREAMS SNU's ONLY): 50+	
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	236,501
	Number of new ANC and L&D clients	248,287
	By: Known positives at entry	4,982
	By: Number of new positives identified	9,013
	Sum of Positives Status disaggregates	13,995
	Required only for DREAMS countries - By known positives: <15	
	Required only for DREAMS countries - By known positives: 15-19	
	Required only for DREAMS countries - By known positives: 20-24	
	Required only for DREAMS countries - By new positives: <15	
	Required only for DREAMS countries - By new positives: 15-19	
	Required only for DREAMS countries - By new positives: 20-24	
	Required only for DREAMS countries - Denominator: <15	



	Required only for DREAMS countries - Denominator: 15-19	
	Required only for DREAMS countries - Denominator: 20-24	
	Required only for DREAMS countries - Denominator: 25-49	
	Required only for DREAMS countries - Denominator: 50+	
	Required only for DREAMS countries - By known positives: 25-49	
	Required only for DREAMS countries - By known positives: 50+	
	Required only for DREAMS countries - By new positives: 25-49	
	Required only for DREAMS countries - By new positives: 50+	
	By Age (DREAMS SNU ^s ONLY): <15	
	By Age (DREAMS SNU ^s ONLY): 15-19	
	By Age (DREAMS SNU ^s ONLY): 20-24	
	By Age (DREAMS SNU ^s ONLY): 25-49	
	By Age (DREAMS SNU ^s ONLY): 50+	
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	



	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	95,797
	New on ART	3,299
	Already on ART at beginning of current pregnancy	2,213
PMTCT_ART_TA	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	236,501
	New on ART	8,619
	Already on ART at beginning of current pregnancy	4,727
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	20,892
	Total number of people in the target population	21,392
	Age/sex: 10-14 Male	



	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	
	Denominator: Age/sex: 25-49 Male	
	Denominator: Age/sex: 50+ Male	
	Denominator: Age/sex: 10-14 Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	
	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for testing as part of program	
	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	100
	Aggregated Age/sex: 15+ Male	19,092
	Aggregated Age/sex: <15 Female	115
	Aggregated Age/sex: 15+ Female	1,585



PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,418
	Total number of people in the target population	21,000
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Age/sex: <15 Male	261
	Aggregated Age/sex: 15+ Male	1,419
	Aggregated Age/sex: <15 Female	1,110
Aggregated Age/sex: 15+ Female	2,628	
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a



	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	24,272
	Total estimated number of key population in the catchment area	36,838
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	8,779
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with	0



	individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	15,493
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0



	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	15,766
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	21,134
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: People in prisons and enclosed settings	0



	(Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: RReturning beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	407,650
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	131
	Age/sex: 15-19 Male	669
	Age/sex: 20-24 Male	2,027
	Age/sex: 25-49 Male	5,301
	Age/sex: 50+ Male	584
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	161
	Age/sex: 15-19 Female	706
	Age/sex: 20-24 Female	2,140
	Age/sex: 25-49 Female	4,467
	Age/sex: 50+ Female	459
	Test Result by Age and Sex: Positive: 10-14 Male	15
	Test Result by Age and Sex: Positive: 15-19 Male	70
Test Result by Age and Sex:	150	



	Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	155
	Test Result by Age and Sex: Positive: 50+ Male	10
	Test Result by Age and Sex: Positive: 10-14 Female	10
	Test Result by Age and Sex: Positive: 15-19 Female	60
	Test Result by Age and Sex: Positive: 20-24 Female	148
	Test Result by Age and Sex: Positive: 25-49 Female	160
	Test Result by Age and Sex: Positive: 50+ Female	5
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex:	



	Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	42,661
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	117,439
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	48,048
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	199,502
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	1,765
	Test Result by Aggregated Age and Sex: Positive 15+ Male	13,966
	Test Result by Aggregated Age and Sex: Positive <15 Female	2,387
	Test Result by Aggregated Age and Sex: Positive 15+ Female	19,964
	Test Result by Age: Positive: <1	0
	Test Result by Age: Positive: 1-9	8
	Age/sex: <1	162
	Age/sex: 1-9	345
	Service Delivery Point (Community): Index testing	
	Service Delivery Point	400



	(Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	13,504
	Service Delivery Point (Community): Other	13,798
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	33,881
	Service Delivery Point (Facility): Outpatient	184,281
	Service Delivery Point (Facility): Pediatric	6,660
	Service Delivery Point (Facility): Malnutrition facilities	0
	Service Delivery Point (Facility): Other PITC	1,922
	Service Delivery Point (Facility): VCT	37,910
	Service Delivery Point (Facility):	148



	VMMC	
	Service Delivery Point (Facility): PMTCT	101,171
	Service Delivery Point (Facility): TB Clinics	11,336
	Service Delivery Point (Facility): Index testing	2,564
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by	



	Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
	HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months
Age/sex: 5-9 Male		
Age/sex: 10-14 Male		
Age/sex: 15-19 Male		
Age/sex: 20-24 Male		
Age/sex: 25-49 Male		
Age/sex: 50+ Male		
Age/sex: 5-9 Female		
Age/sex: 10-14 Female		
Age/sex: 15-19 Female		
Age/sex: 20-24 Female		
Age/sex: 25-49 Female		
Age/sex: 50+ Female		
Test Result by Age and Sex: Positive: 10-14 Male		
Test Result by Age and Sex: Positive: 15-19 Male		



	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	



	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	75,511
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	164,124
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	78,359
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	325,271
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	2,265
	Test Result by Aggregated Age and Sex: Positive 15+ Male	16,497
	Test Result by Aggregated Age and Sex: Positive <15 Female	2,769
	Test Result by Aggregated Age and Sex: Positive 15+ Female	26,836
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	



	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	48,464
	Service Delivery Point (Facility): Outpatient	341,070
	Service Delivery Point (Facility): Pediatric	13,302
	Service Delivery Point (Facility): Malnutrition facilities	5
	Service Delivery Point (Facility): Other PITC	2,819



	Service Delivery Point (Facility): VCT	284
	Service Delivery Point (Facility): VMMC	0
	Service Delivery Point (Facility): PMTCT	225,474
	Service Delivery Point (Facility): TB Clinics	9,385
	Service Delivery Point (Facility): Index testing	2,481
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	



	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	8,079
	Total number of registered new and relapsed TB cases, during the reporting period.	8,977
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status,	



	during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	364
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,567
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	663
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,485
	Result: Known HIV positive at	



	service entry	
	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	



	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a



	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,222
	Total number of registered new and relapsed TB cases, during the reporting period.	3,584
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with	



	documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the	119



	reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,230
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	171
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,702
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB	



	cases, during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	11,000
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	



	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	
	Sum of Age/Sex disaggregates	
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	



	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
	Required only for DREAMS countries - By service, age and	



	sex: Parenting/Caregiver Programs Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	



	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male	



	<1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	



	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	
	Program Completion: Active	
	Program Completion: Graduation	
	Program Completion: Transferred	



	Program Completion: Exited without graduation	
	By Aggregated Age/Sex: <18 Male	5,604
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	5,396
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	774
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-9 Male	
	Age/Sex: 10-14 Male	



	Age/Sex: 15-17 Male	
	By age/sex: 18-24 Male	
	By age/sex: 25+ Male	
	Age/Sex: 18+ Male	153
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-9 Female	
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By age/sex: 18-24 Female	
	By age/sex: 25+ Female	
	Age/Sex: 18+ Female	196
	Sum of Age/Sex disaggregates	349
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17	
	Required only for DREAMS	



	countries: By Service Area, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 25+	



	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver	



	Program Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 5-9	
	Required only for DREAMS countries: By Service Area, age	



	and sex: Social Protection Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 18-24	



	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening	



	Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 1-4	
	Required only for DREAMS countries: By Service Area, age	



	and sex: Other Service Areas Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening 1-9	
	Required only for DREAMS	



	countries: By Service Area, age and sex: Other Service Areas <1	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 25+	
	By Aggregated Age/Sex: <18 Male	
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Program 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening 1-9 Female	



	Required only for DREAMS countries - By service, age and sex: Other Service Areas 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Social Protection 1-9 Female	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas 1-9	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	4,744
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	5,077
	Age/Sex: >1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	



	<p>Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during</p>	



	the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	189
	Aggregated Age/Sex: Male 15+	1,614



	(Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	328
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,611
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of	



	registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented	



	HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB	



	treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,565
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	2,697



	period	
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during	



	the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator:	



	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	88
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,000
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	124
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,353
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: <1 (Denominator: The	



	number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented	



	HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	43,331
	Screened for TB by Age/Sex:<15 Male	1,467
	Screened for TB by Age/Sex: 15+ Male	10,544
	Screened for TB by Age/Sex:<15 Female	2,519
	Screened for TB by Age/Sex: 15+ Female	23,088
	Screen Result: Screened Positive for TB	15,639
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	13,899
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	9,498
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	2,413
[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0	
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	45,391



	Screened for TB by Age/Sex: <15 Male	1,558
	Screened for TB by Age/Sex: 15+ Male	10,747
	Screened for TB by Age/Sex: <15 Female	2,456
	Screened for TB by Age/Sex: 15+ Female	25,175
	Screen Results: Screened Positive for TB	16,521
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	14,179
	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	11,442
	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	568
	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	0
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant	



	women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	4,021
	By infants who received their first virologic HIV test between 2 and 12 months of age	1,814
	Sum of Infant Age disaggregates	5,835
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	101
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	69
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant	



	women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	8,259
	By infants who received their first virologic HIV test between 2 and 12 months of age	4,764
	Sum of Infant Age disaggregates	13,023
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	260
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	392
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	97,134
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	



	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	3,620
	Aggregated Age/Sex: 15+ Male	26,768
	Aggregated Age/Sex: <15 Female	5,813
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	60,935
	Sum of Aggregated Age/Sex <15	9,433
	Sum of Aggregated Age/Sex 15+	87,703
	Sum of Aggregated Age/Sex disaggregates	97,136
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	76,602
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	



	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	1,279
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	23,031
	Aggregated Age/Sex: <15 Female	2,153
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	50,182
	Sum of Aggregated Age/Sex <15	3,432
	Sum of Aggregated Age/Sex 15+	73,213
	Sum of Aggregated Age/Sex disaggregates	76,645
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	49,204



	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	1,200
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	15,779
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	1,761
	Aggregated Grouping by Age/Sex: 15+ Female	30,464
	Sum of Aggregated Age/Sex disaggregates	49,204
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex:	



	1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	39,518
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	458
Aggregated Grouping by Age/Sex: 1-14 Male		
Aggregated Grouping by Age/Sex: 15+ Male	11,864	
Aggregated Grouping by Age: <1		



	Female	
	Aggregated Grouping by Age/Sex: <15 Female	818
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	25,953
	Sum of Aggregated Age/Sex disaggregates	39,093
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	32,176
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	35,760
	Numerator: Indication: Routine	31,664
	Numerator: Indication: Targeted	512
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	



	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	



	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	



	Denominator: Indication: Routine	35,090
	Denominator: Indication: Targeted	670
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	



	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	



	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	1,145
	Numerator Aggregated Age/Sex: 15+ Male	8,678
	Numerator Aggregated Age/Sex: <15 Female	1,741
	Numerator Aggregated Age/Sex: 15+ Female	20,612
	Denominator Aggregated Age/Sex: <15 Male	1,273
	Denominator Aggregated Age/Sex: 15+ Male	10,757
	Denominator Aggregated Age/Sex: <15 Female	1,937
	Denominator Aggregated Age/Sex: 15+ Female	21,839
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	7,232



	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	8,019
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication:	



	20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by	



	Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	6,863
	Numerator: Indication: Targeted	369
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	7,568
	Denominator: Indication: Targeted	450
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by	



	Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex	



	by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	193
	Numerator Aggregated Age/Sex: 15+ Male	1,978
	Numerator Aggregated Age/Sex: <15 Female	309
	Numerator Aggregated Age/Sex: 15+ Female	4,752
	Denominator Aggregated Age/Sex: <15 Male	197
	Denominator Aggregated Age/Sex: 15+ Male	2,107
	Denominator Aggregated Age/Sex: <15 Female	331
	Denominator Aggregated Age/Sex: 15+ Female	5,382
TX_RET_DSD	TX_RET_DSD Percent of adults	n/a



	and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	34,663
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	47,323
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who	



	are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped	



	ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	



	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,105
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,243
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,648
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	20,667
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	1,476



	including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14,667
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,184
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	27,772
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	26,680
	Total number of adults and children who initiated ART in the 12 months	41,061



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and	



	children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	



	<p>Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the</p>	



	reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	



	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	



	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	651
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,319
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,095
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17,610
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,056
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	11,021



	those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,712
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	27,309
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	900
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	630
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	441
	CD4: Number of laboratories that perform this testing	



	CD4: Number of laboratories that participate in this PT program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	Early infant diagnostics: Number of laboratories that perform this testing	
	Early infant diagnostics: Number of laboratories that participate in this PT program	
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	HIV viral load: Number of laboratories that perform this testing	
	HIV viral load: Number of laboratories that participate in this PT program	
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	



	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program
CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program		79
CD4: Number of laboratories that participate in this PT program		112
CD4: Number of laboratories that perform this testing		160
Early infant diagnostics: Number of laboratories that achieve		3



	acceptable successful passing criteria in this PT program	
	Early infant diagnostics: Number of laboratories that participate in this PT program	3
	Early infant diagnostics: Number of laboratories that perform this testing	3
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
	HIV viral load: Number of laboratories that participate in this PT program	6
	HIV viral load: Number of laboratories that perform this testing	6
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	5



	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	5
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	1
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	1
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	100
	By Graduates: Doctors	
	By Graduates: Nurses	50
	By Graduates: Midwives	50
	By Graduates: Social service workers	
	By Graduates: Laboratory	



	professionals	
	By Graduates: Other	
	Sum of Graduates disaggreagtes	100
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	4,056,144
	Number of HIV Test Kits purchased	150,000
	Number of HIV CD4 Reagents purchased	
	Number of Condoms purchased	
	Number of HIV Viral Load Reagents purchased	1,906,144
	Number of HIV ARVs purchased	2,000,000
	Number of Second Line HIV ARVs purchased	
	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	
	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	
	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	
	Condoms: Dollars planned (COP)/ spent (Actual)	
	HIV ARVs: Dollars planned (COP)/ spent (Actual)	



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
12937	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	323,429
13799	Global Health Systems Solutions	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14118	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	75,000
16743	Care International	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	3,809,191
16744	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	1,739,126
16816	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	562,500



			Prevention		
17336	Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,005,059
17361	Cameroon Baptist Convention Health Board	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	14,025,004
17364	Population Services International	NGO	U.S. Department of Defense	GHP-State	28,335
17365	Metabiota	Private Contractor	U.S. Department of Defense	GHP-State	525,250
18049	FHI 360	NGO	U.S. Agency for International Development	GHP-State	360,000
18080	Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	429,825
18195	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	1,877,113
18228	TBD	TBD	Redacted	Redacted	Redacted
18229	TBD	TBD	Redacted	Redacted	Redacted

Approved



18230	TBD	TBD	Redacted	Redacted	Redacted
18459	Columbia University	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	145,000



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 12937	Mechanism Name: Capacity Strengthening for Peace Corps Volunteers and Counterparts
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 323,429	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 323,429	
Funding Source	Funding Amount
GHP-State	323,429

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12937		
Mechanism Name:	Capacity Strengthening for Peace Corps Volunteers and Counterparts		
Prime Partner Name:	U.S. Peace Corps		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	119,669	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HKID	58,217	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	145,543	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,418
PP_PREV_TA	Total number of people in the target population	21,000
PP_PREV_TA	Aggregated Age/sex: <15 Male	261
PP_PREV_TA	Aggregated Age/sex: 15+ Male	1,419
PP_PREV_TA	Aggregated Age/sex: <15 Female	1,110
PP_PREV_TA	Aggregated Age/sex: 15+ Female	2,628
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	190
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	251
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	774
OVC_SERV_TA	Age/Sex: 18+ Male	153
OVC_SERV_TA	Age/Sex: 18+ Female	196
OVC_SERV_TA	Sum of Age/Sex disaggregates	349

Implementing Mechanism Details

Mechanism ID: 13799	Mechanism Name: GHSS-Strengthening Public Health Laboratory Systems in Cameroon
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Global Health Systems Solutions	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



G2G: No	Managing Agency:
Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13799			
Mechanism Name: GHSS-Strengthening Public Health Laboratory Systems in Cameroon			
Prime Partner Name: Global Health Systems Solutions			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	900
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	630
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	441
LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	79
LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	112
LAB_PT_TA	CD4: Number of laboratories that perform this testing	160
LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
LAB_PT_TA	Early infant diagnostics: Number of laboratories that participate in this PT program	3
LAB_PT_TA	Early infant diagnostics: Number of laboratories that perform this testing	3
LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
LAB_PT_TA	HIV viral load: Number of laboratories that participate in	6



	this PT program	
LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	6
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	5
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	5
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	1
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	1

Implementing Mechanism Details

Mechanism ID: 14118	Mechanism Name: Strengthening Clinical Laboratory Workforce
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 75,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 75,000	
Funding Source	Funding Amount
GHP-State	75,000



Cross-Cutting Budget Attribution(s)

Human Resources for Health	10,500
----------------------------	--------

Budget Code Information

Mechanism ID:	14118		
Mechanism Name:	Strengthening Clinical Laboratory Workforce		
Prime Partner Name:	African Society for Laboratory Medicine		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	75,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16743	Mechanism Name: Continuum of Prevention, Care, and Treatment for HIV/AIDS with MARPs in Cameroon (CHAMP)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Care International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 3,809,191	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,809,191	
Funding Source	Funding Amount
GHP-State	3,574,400



GHP-USAID	234,791
-----------	---------

Cross-Cutting Budget Attribution(s)

Human Resources for Health	811,537
Food and Nutrition: Policy, Tools, and Service Delivery	30,000
Food and Nutrition: Commodities	30,000
Key Populations: MSM and TG	1,886,805
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	1,886,805
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	55,000
Focus Area:	Post GBV Care



Sub Area:	Implementation
Motor Vehicles: Purchased	150,000

Budget Code Information

Mechanism ID:	16743		
Mechanism Name:	Continuum of Prevention, Care, and Treatment for HIV/AIDS with MARPs in Cameroon (CHAMP)		
Prime Partner Name:	Care International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,482,506	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	468,701	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,857,984	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a	17,892



	standardized HIV prevention intervention including the minimum components during the reporting period.	
PP_PREV_DSD	Total number of people in the target population	17,892
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	17,892
PP_PREV_DSD	Aggregated Age/sex: <15 Female	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	0
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	24,272
KP_PREV_DSD	Total estimated number of key population in the catchment area	36,838
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	8,779
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with	15,493



	individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	15,766
KP_PREV_DSD	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	21,134
KP_PREV_DSD	By key population type: Males who inject drugs (Male	0



	PWID) (Denominator: Total estimated number of key population in the catchment area)	
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	18,668
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,190
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	7,726
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,194
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	8,558
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,384
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	16,284
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	18,668
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	110
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,504
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	112
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,732
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	4,870
HTC_TST_DSD	Service Delivery Point (Community): Other	13,798

Implementing Mechanism Details



Mechanism ID: 16744	Mechanism Name: Key Interventions for Developing Systems and Services for Orphans and Vulnerable Children populations in Cameroon (KIDSS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,739,126	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,739,126	
Funding Source	Funding Amount
GHP-State	1,739,126

Cross-Cutting Budget Attribution(s)

Human Resources for Health	340,308
Economic Strengthening	9,890
Gender: GBV	41,300
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Food and Nutrition: Commodities	49,233
Water	25,000



Budget Code Information

Mechanism ID:	16744		
Mechanism Name:	Key Interventions for Developing Systems and Services for Orphans and Vulnerable Children populations in Cameroon (KIDSS)		
Prime Partner Name:	Catholic Relief Services		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	349,939	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,389,187	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	11,000
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	5,604
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	5,396

Implementing Mechanism Details

Mechanism ID: 16816	Mechanism Name: Technical Assistance support in assessing HIV service delivery in Cameroon
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 562,500	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 562,500	
Funding Source	Funding Amount
GHP-State	562,500

Cross-Cutting Budget Attribution(s)

Human Resources for Health	50,000
----------------------------	--------

Budget Code Information

Mechanism ID:	16816		
Mechanism Name:	Technical Assistance support in assessing HIV service delivery in		
Prime Partner Name:	Cameroon		
	Elizabeth Glaser Pediatric AIDS Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	281,250	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	281,250	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17336	Mechanism Name: Columbia ICAP 2014 CDC HQ mech
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,005,059	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,005,059	
Funding Source	Funding Amount
GHP-State	1,005,059

Cross-Cutting Budget Attribution(s)

Human Resources for Health	45,000
----------------------------	--------

Budget Code Information

Mechanism ID: 17336			
Mechanism Name: Columbia ICAP 2014 CDC HQ mech			
Prime Partner Name: Columbia University			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	55,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	90,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	860,059	0

Implementing Mechanism Indicator Information

Approved



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17361	Mechanism Name: CBCHB - PMTCT-ART Center-Littoral 2015
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Cameroon Baptist Convention Health Board	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 14,025,004	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 14,025,004	
Funding Source	Funding Amount
GHP-State	14,025,004

Cross-Cutting Budget Attribution(s)

Human Resources for Health	500,000
----------------------------	---------

Budget Code Information

Mechanism ID:	17361		
Mechanism Name:	CBCHB - PMTCT-ART Center-Littoral 2015		
Prime Partner Name:	Cameroon Baptist Convention Health Board		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	1,103,032	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,637,652	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,546,630	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	7,478,343	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	2,259,347	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	73,449
PMTCT_ART_DSD	New on ART	2,563
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,538
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	134,325
PMTCT_ART_TA	New on ART	5,201
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	2,388
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	73,449
PMTCT_STAT_DSD	Number of new ANC and L&D clients	76,833
PMTCT_STAT_DSD	By: Known positives at entry	1,576
PMTCT_STAT_DSD	By: Number of new positives identified	2,851
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	4,427
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	134,325



PMTCT_STAT_TA	Number of new ANC and L&D clients	140,852
PMTCT_STAT_TA	By: Known positives at entry	2,561
PMTCT_STAT_TA	By: Number of new positives identified	5,328
PMTCT_STAT_TA	Sum of Positives Status disaggregates	7,889
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	273,817
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	25,421
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	77,888
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	33,912
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	136,596
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	59,333
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	214,484
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	273,817
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	1,232
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	9,202
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1,903
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	12,815
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	23,882
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	120,753
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	4,488
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	1,800
HTC_TST_DSD	Service Delivery Point (Facility): VCT	37,910
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	148



HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	76,866
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	6,747
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	1,223
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	337,810
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	34,107
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	97,322
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	42,752
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	163,629
HTC_TST_TA	Sum of Aggregated Age/Sex <15	76,859
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	260,951
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	337,810
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	1,259
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	9,782
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	1,821
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	12,486
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	25,244
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	169,658
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	7,708
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	2,342
HTC_TST_TA	Service Delivery Point (Facility): VCT	284
HTC_TST_TA	Service Delivery Point (Facility): VMMC	0
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	125,667



HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	6,238
HTC_TST_TA	Service Delivery Point (Facility): Index testing	668
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	6,695
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	7,441
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	324
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,840
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	628
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,903
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,971
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	2,195
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	97
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	585
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	152
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,137



TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	3,524
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	3,783
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	172
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	984
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	313
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,053
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,438
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,540
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	72
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	418



	TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	111
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	837
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	27,906
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	1,288
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	7,193
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	2,340
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	17,085
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	9,906
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	8,282
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	7,542
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	520
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	27,734
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	1,409
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	7,856
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	2,298
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	16,172
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	11,197
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent:	9,248



	Specimen sent for bacteriologic diagnosis of active TB	
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	8,656
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	263
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,822
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,384
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,206
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	82
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	50
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	4,141
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	3,343
PMTCT_EID_TA	Sum of Infant Age disaggregates	7,484
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	207
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	269
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	55,203
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,413
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	16,412
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,576
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	34,804
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,989
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	51,216



TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	55,205
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	50,318
TX_CURR_TA	Aggregated Age/Sex: <15 Male	828
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	15,934
TX_CURR_TA	Aggregated Age/Sex: <15 Female	1,599
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	31,996
TX_CURR_TA	Sum of Aggregated Age/Sex <15	2,427
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	47,930
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	50,357
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	29,916
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	690
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	9,064
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,070
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	19,092
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	29,916
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	25,723
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	294
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	8,160
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	639
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	16,205
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	25,298
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	28,182
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	31,312
TX_PVLS_DSD	Numerator: Indication: Routine	28,182
TX_PVLS_DSD	Numerator: Indication: Targeted	0



TX_PVLS_DSD	Denominator: Indication: Routine	31,312
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	1,043
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	7,285
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	1,620
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	18,234
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1,160
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	9,206
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,802
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	19,190
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	4,530
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	5,032
TX_PVLS_TA	Numerator: Indication: Routine	4,196
TX_PVLS_TA	Numerator: Indication: Targeted	334
TX_PVLS_TA	Denominator: Indication: Routine	4,660
TX_PVLS_TA	Denominator: Indication: Targeted	371
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	151
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	1,293
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	254
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	2,832
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	149
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	1,353
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	259
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	3,271
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	23,012
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting	29,913



	period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	814
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,095
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,288
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13,815
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,017
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,755
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,634
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	17,282
TX_RET_TA	Number of adults and children who are still alive and on	16,622



	treatment at 12 months after initiating ART	
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	25,723
TX_RET_TA	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	526
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,692
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	942
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,462
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	868
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,301



TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,496
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	16,057

Implementing Mechanism Details

Mechanism ID: 17364	Mechanism Name: Prevention activities with Cameroon Military
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 28,335	
Applied Pipeline Amount: 300,652	
Total All Funding Sources and Applied Pipeline Amount: 328,987	
Funding Source	Funding Amount
GHP-State	28,335

Cross-Cutting Budget Attribution(s)

Condom procurement	10,000
Water	10,000
Gender: Gender Equality	8,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building



Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation

Budget Code Information

Mechanism ID:	17364		
Mechanism Name:	Prevention activities with Cameroon Military		
Prime Partner Name:	Population Services International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	4,696	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	13,810	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	9,829	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,000
PP_PREV_DSD	Total number of people in the target population	3,500
PP_PREV_DSD	Aggregated Age/sex: <15 Male	100
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	1,200
PP_PREV_DSD	Aggregated Age/sex: <15 Female	115
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	1,585
HTC_TST_DSD	Number of individuals who received T&C services for	9,034



	HIV and received their test results during the past 12 months	
HTC_TST_DSD	Age/sex: 10-14 Male	50
HTC_TST_DSD	Age/sex: 15-19 Male	500
HTC_TST_DSD	Age/sex: 20-24 Male	1,000
HTC_TST_DSD	Age/sex: 25-49 Male	3,000
HTC_TST_DSD	Age/sex: 50+ Male	100
HTC_TST_DSD	Age/sex: 10-14 Female	80
HTC_TST_DSD	Age/sex: 15-19 Female	550
HTC_TST_DSD	Age/sex: 20-24 Female	1,300
HTC_TST_DSD	Age/sex: 25-49 Female	2,384
HTC_TST_DSD	Age/sex: 50+ Female	50
HTC_TST_DSD	Sum of Age/Sex disaggregates	9,014
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	15
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	70
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	150
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	155
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	10
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	10
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	60
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	148
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	160
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	5
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	60
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,600
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	90
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,284
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	150



HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	8,884
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	9,034
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	18
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	385
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	15
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	373
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	8
HTC_TST_DSD	Age/sex: <1	0
HTC_TST_DSD	Age/sex: 1-9	20
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	400
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	8,634

Implementing Mechanism Details

Mechanism ID: 17365	Mechanism Name: Strengthening Lab & MTCT Services in the military
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Metabiota	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 525,250	
Applied Pipeline Amount: 400,000	
Total All Funding Sources and Applied Pipeline Amount: 925,250	
Funding Source	Funding Amount
GHP-State	525,250



Cross-Cutting Budget Attribution(s)

Human Resources for Health	30,000
Renovation	18,000
Gender: GBV	6,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building

Budget Code Information

Mechanism ID: 17365			
Mechanism Name: Strengthening Lab & MTCT Services in the military			
Prime Partner Name: Metabiota			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	15,687	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	5,387	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	21,469	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	429,511	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	53,196	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,444
PMTCT_ART_DSD	New on ART	154
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	40
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,444
PMTCT_STAT_DSD	Number of new ANC and L&D clients	3,444
PMTCT_STAT_DSD	By: Known positives at entry	40
PMTCT_STAT_DSD	By: Number of new positives identified	154
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	194
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	8,118
HTC_TST_DSD	Age/sex: 10-14 Male	81
HTC_TST_DSD	Age/sex: 15-19 Male	169
HTC_TST_DSD	Age/sex: 20-24 Male	1,027
HTC_TST_DSD	Age/sex: 25-49 Male	2,301
HTC_TST_DSD	Age/sex: 50+ Male	484
HTC_TST_DSD	Age/sex: 10-14 Female	81
HTC_TST_DSD	Age/sex: 15-19 Female	156
HTC_TST_DSD	Age/sex: 20-24 Female	840
HTC_TST_DSD	Age/sex: 25-49 Female	2,083
HTC_TST_DSD	Age/sex: 50+ Female	409
HTC_TST_DSD	Sum of Age/Sex disaggregates	7,631
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	360
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,980
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	290

HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,488
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	650
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	7,468
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	8,118
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	34
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	372
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	27
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	326
HTC_TST_DSD	Age/sex: <1	162
HTC_TST_DSD	Age/sex: 1-9	325
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	1,567
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	1,801
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	843
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	3,444
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	63
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	400
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	63
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	70
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	33
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1



TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	27
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	22
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	63
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	11
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	1,425
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	10
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	531
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	18
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	866
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	570
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	570

TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	570
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	159
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	35
PMTCT_EID_DSD	Sum of Infant Age disaggregates	194
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	8
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	1
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	4,320
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	32
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,566
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	27
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,695
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	59
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	4,261
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	4,320
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,426
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	64
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	699
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	50
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	613
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,426
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	939
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record	1,044



	and /or laboratory records in the past 12 months.	
TX_PVLS_DSD	Numerator: Indication: Routine	439
TX_PVLS_DSD	Numerator: Indication: Targeted	500
TX_PVLS_DSD	Denominator: Indication: Routine	400
TX_PVLS_DSD	Denominator: Indication: Targeted	644
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	7
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	340
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	6
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	586
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	8
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	378
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	7
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	651
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,141
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,426
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	414
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	712
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	10



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	518
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	889

Implementing Mechanism Details

Mechanism ID: 18049	Mechanism Name: LINKAGES
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 360,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 360,000	
Funding Source	Funding Amount
GHP-State	360,000

Cross-Cutting Budget Attribution(s)



Key Populations: FSW	180,000
Focus Area:	Training of health workers and community outreach workers
Key Populations: MSM and TG	180,000

Budget Code Information

Mechanism ID: 18049			
Mechanism Name: LINKAGES			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	125,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	35,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	150,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18080	Mechanism Name: ICAP - PMTCT-ART Center-Littoral 2015
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 429,825	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 429,825	
Funding Source	Funding Amount
GHP-State	429,825

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18080		
Mechanism Name:	ICAP - PMTCT-ART Center-Littoral 2015		
Prime Partner Name:	Columbia University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	47,030	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	111,640	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	256,776	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	14,379	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,746
PMTCT_ART_DSD	New on ART	80
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	51
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	27,763
PMTCT_ART_TA	New on ART	1,219
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	449
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,746
PMTCT_STAT_DSD	Number of new ANC and L&D clients	1,838
PMTCT_STAT_DSD	By: Known positives at entry	53
PMTCT_STAT_DSD	By: Number of new positives identified	84
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	137
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	27,763
PMTCT_STAT_TA	Number of new ANC and L&D clients	29,226
PMTCT_STAT_TA	By: Known positives at entry	714
PMTCT_STAT_TA	By: Number of new positives identified	1,042
PMTCT_STAT_TA	Sum of Positives Status disaggregates	1,756
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	15,868
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	476



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,332
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	476
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	11,584
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	952
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	14,916
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	15,868
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	13
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	122
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	13
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,070
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	1,410
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	10,576
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	131
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	122
HTC_TST_DSD	Service Delivery Point (Facility): VCT	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	3,272
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	282
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	76,114
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,285
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	15,983
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,285



HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	55,561
HTC_TST_TA	Sum of Aggregated Age/Sex <15	4,570
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	71,544
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	76,114
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	45
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	479
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	45
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	4,197
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	5,427
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	40,688
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	1,608
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	477
HTC_TST_TA	Service Delivery Point (Facility): VCT	0
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	26,850
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	1,084
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	154
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	171
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	76
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number	74



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	777
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	863
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	15
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	381
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	374
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	138
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	138
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	68
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	1



	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	66
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	699
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	699
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	13
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	343
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	337
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	1,218
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	13
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	122
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	13
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	1,070
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	488

TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	390
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	312
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	78
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	4,766
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	45
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	479
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	45
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	4,197
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	1,906
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,527
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	1,222
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	305
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	76
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	55
PMTCT_EID_DSD	Sum of Infant Age disaggregates	131
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	6
PMTCT_EID_TA	By infants who received a virologic test within 2 months	970



	of birth	
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	698
PMTCT_EID_TA	Sum of Infant Age disaggregates	1,668
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	10
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	107
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,658
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	53
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	623
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	53
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,929
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	106
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	2,552
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,658
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	7,670
TX_CURR_TA	Aggregated Age/Sex: <15 Male	71
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	2,019
TX_CURR_TA	Aggregated Age/Sex: <15 Female	94
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	5,486
TX_CURR_TA	Sum of Aggregated Age/Sex <15	165
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	7,505
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	7,670
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,353
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	27
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	219
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	11
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,096
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,353



TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,631
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	36
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	882
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	22
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	3,691
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	4,631
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	239
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	265
TX_PVLS_DSD	Numerator: Indication: Routine	227
TX_PVLS_DSD	Numerator: Indication: Targeted	12
TX_PVLS_DSD	Denominator: Indication: Routine	239
TX_PVLS_DSD	Denominator: Indication: Targeted	26
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	3
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	62
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	3
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	171
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	3
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	69
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	3
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	190
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	693
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	767



TX_PVLS_TA	Numerator: Indication: Routine	658
TX_PVLS_TA	Numerator: Indication: Targeted	35
TX_PVLS_TA	Denominator: Indication: Routine	688
TX_PVLS_TA	Denominator: Indication: Targeted	79
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	4
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	181
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	4
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	504
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	5
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	197
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	5
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	560
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	880
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,353
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	229
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	631
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	27



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	219
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,097
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,008
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,631
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	28
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	782
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	28
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,170
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total	38



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	895
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	27
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,672
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	100
HRH_PRE	By Graduates: Nurses	50
HRH_PRE	By Graduates: Midwives	50
HRH_PRE	Sum of Graduates disaggreagtes	100

Implementing Mechanism Details

Mechanism ID: 18195	Mechanism Name: Global Health Supply Chain Program
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:



Total All Funding Sources: 1,877,113	
Applied Pipeline Amount: 4,000,000	
Total All Funding Sources and Applied Pipeline Amount: 5,877,113	
Funding Source	Funding Amount
GHP-State	1,877,113

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	135,000
---------------------------	---------

Budget Code Information

Mechanism ID:	18195		
Mechanism Name:	Global Health Supply Chain Program		
Prime Partner Name:	Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,829,898	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	47,215	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	4,056,144
INVS_COMD	Number of HIV Test Kits purchased	150,000
INVS_COMD	Number of HIV Viral Load Reagents purchased	1,906,144



INVS_COMD	Number of HIV ARVs purchased	2,000,000
-----------	------------------------------	-----------

Implementing Mechanism Details

Mechanism ID: 18228	Mechanism Name: ART services in 8 regions
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: TBD	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 2,811,448	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,811,448	
Funding Source	Funding Amount
GHP-State	2,811,448

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18228		
Mechanism Name:	ART services in 8 regions		
Prime Partner Name:	TBD		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	135,582	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	304,211	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	321,853	0
Treatment	HTXS	899,978	0
Treatment	PDTX	1,149,824	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	17,158
PMTCT_ART_DSD	New on ART	502
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	584
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	74,413
PMTCT_ART_TA	New on ART	2,199
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,890
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	17,158
PMTCT_STAT_DSD	Number of new ANC and L&D clients	18,037
PMTCT_STAT_DSD	By: Known positives at entry	505
PMTCT_STAT_DSD	By: Number of new positives identified	612
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,117
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	74,413
PMTCT_STAT_TA	Number of new ANC and L&D clients	78,209



PMTCT_STAT_TA	By: Known positives at entry	1,707
PMTCT_STAT_TA	By: Number of new positives identified	2,643
PMTCT_STAT_TA	Sum of Positives Status disaggregates	4,350
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	82,145
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	15,154
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	19,913
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	12,086
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	34,992
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	27,240
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	54,905
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	82,145
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	358
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,381
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	317
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	3,648
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	7,022
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	51,151
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	1,198
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	0
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	17,589



HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	4,244
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	941
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	229,341
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	39,119
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	50,819
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	33,322
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	106,081
HTC_TST_TA	Sum of Aggregated Age/Sex <15	72,441
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	156,900
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	229,341
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	961
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	6,236
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	903
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	10,153
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	17,793
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	130,724
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	3,986
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	5
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	0
HTC_TST_TA	Service Delivery Point (Facility): VCT	0
HTC_TST_TA	Service Delivery Point (Facility): VMMC	0
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	72,957
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	2,063



HTC_TST_TA	Service Delivery Point (Facility): Index testing	1,813
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,167
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,295
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	35
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	618
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	33
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	481
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	474
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	526
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	264
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	191
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART	1,060



	during TB treatment during the reporting period	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,093
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	13
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	552
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	14
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	481
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	428
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	458
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	239
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The	7

	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	179
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	12,782
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	156
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	2,698
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	148
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	4,067
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	4,675
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	4,657
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	1,074
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,815
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	12,891
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	104
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	2,412
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	113
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	4,806
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	3,418
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	3,404
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear	1,564

	Only	
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	0
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	964
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	340
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,304
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	11
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	12
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	3,148
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	723
PMTCT_EID_TA	Sum of Infant Age disaggregates	3,871
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	43
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	16
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	34,953
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,122
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	8,167
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	3,157
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	21,507
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	5,279
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	29,674
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	34,953
TX_CURR_TA	Number of adults and children receiving antiretroviral	18,614



	therapy (ART)	
TX_CURR_TA	Aggregated Age/Sex: <15 Male	380
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	5,078
TX_CURR_TA	Aggregated Age/Sex: <15 Female	460
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	12,700
TX_CURR_TA	Sum of Aggregated Age/Sex <15	840
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	17,778
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	18,618
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	16,509
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	419
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	5,797
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	630
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	9,663
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	16,509
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	9,164
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	128
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	2,822
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	157
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	6,057
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	9,164
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	2,816
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	3,139
TX_PVLS_DSD	Numerator: Indication: Routine	2,816
TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Indication: Routine	3,139
TX_PVLS_DSD	Denominator: Indication: Targeted	0



TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	92
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	991
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	112
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	1,621
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	102
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	1,104
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	125
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	1,808
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	2,009
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	2,220
TX_PVLS_TA	Numerator: Indication: Routine	2,009
TX_PVLS_TA	Numerator: Indication: Targeted	0
TX_PVLS_TA	Denominator: Indication: Routine	2,220
TX_PVLS_TA	Denominator: Indication: Targeted	0
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	38
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	504
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	51
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	1,416
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	43
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	557
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	67
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	1,551
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	9,630
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	14,631



TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	273
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,505
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	343
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,509
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	422
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,175
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	530
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,504
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,050
TX_RET_TA	Total number of adults and children who initiated ART	10,707



	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	97
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,845
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	125
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,978
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	150
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,825
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	189
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,580



Implementing Mechanism Details

Mechanism ID: 18229	Mechanism Name: Strengthening the Capacity of the National AIDS Control Committee
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: TBD	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 873,797	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 873,797	
Funding Source	Funding Amount
GHP-State	873,797

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18229		
Mechanism Name:	Strengthening the Capacity of the National AIDS Control Committee		
Prime Partner Name:	TBD		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	362,728	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	29,547	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	17,250	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	18,750	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	438,175	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	7,347	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18230	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18459	Mechanism Name: Global Nursing Capacity Building Program
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 145,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 145,000	



Funding Source	Funding Amount
GHP-State	145,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18459			
Mechanism Name: Global Nursing Capacity Building Program			
Prime Partner Name: Columbia University			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	145,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Agency Information - Costs of Doing Business
U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services			3,000	0	3,000	3,000
ICASS			273,876	0	273,876	273,876



Indirect Costs			27,500	0	27,500	27,500
Management Meetings/Professional Development			20,000	0	20,000	20,000
Non-ICASS Administrative Costs			200,930	0	200,930	200,930
Staff Program Travel			75,000	0	75,000	75,000
USG Staff Salaries and Benefits - Internationally Recruited		0	509,272	0	509,272	509,272
USG Staff Salaries and Benefits - Locally Recruited		0	155,631	0	155,631	155,631
Total	0	0	1,265,209	0	1,265,209	1,265,209

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		0		20,000	0	20,000



ICASS		0		20,000	0	20,000
Management Meetings/Professional Development		0		10,000	0	10,000
Staff Program Travel				20,000	0	20,000
USG Staff Salaries and Benefits - Locally Recruited				104,000	0	104,000
Total	0	0	0	174,000	0	174,000

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing		97,981		0	97,981	97,981
Computers/IT Services		213,284		0	213,284	213,284
ICASS		371,680		1,013,057	371,680	1,384,737
Institutional Contractors		100,000		0	100,000	100,000
Management Meetings/Profes		20,000		0	20,000	20,000



sional Development						
Non-ICASS Administrative Costs		247,064		0	247,064	247,064
Staff Program Travel		49,575		500,000	49,575	549,575
USG Staff Salaries and Benefits - Internationally Recruited	0	0		0	0	0
USG Staff Salaries and Benefits - Locally Recruited	575,119	1,233,970		0	1,809,089	1,809,089
Total	575,119	2,333,554	0	1,513,057	2,908,673	4,421,730

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		5,000		0	5,000	5,000
ICASS		33,817		0	33,817	33,817
Institutional Contractors		24,000		0	24,000	24,000



Management Meetings/Professional Development		30,000		0	30,000	30,000
Non-ICASS Administrative Costs		84,250		0	84,250	84,250
Staff Program Travel		44,183		0	44,183	44,183
USG Staff Salaries and Benefits - Locally Recruited		80,000		0	80,000	80,000
Total	0	301,250	0	0	301,250	301,250

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Institutional Contractors		332,140		0	332,140	332,140
Non-ICASS Administrative Costs		177,311		0	177,311	177,311
Peace Corps Volunteer Costs				0	0	0
Staff Program		41,257		0	41,257	41,257

Approved



Travel						
USG Staff Salaries and Benefits - Locally Recruited		81,374		0	81,374	81,374
Total	0	632,082	0	0	632,082	632,082